Peptide · Approved

Icatibant

A bradykinin B2-receptor antagonist (Firazyr) that stops hereditary-angioedema attacks.

Key facts

  • Also known as: Firazyr
  • Status: Approved
  • Used for: Hereditary angioedema
  • Natural counterpart: Blocks the receptor for natural bradykinin.
  • Target enzyme / receptor: Bradykinin B2 receptor (BDKRB2) — GPCR (antagonist)
  • Signalling pathway: Blocks Gαq signalling → prevents vascular leak & swelling
    In plain terms: Blocks bradykinin’s receptor to stop the fluid leak that causes swelling.
  • Crystal / cryo-EM structure: Available  PDB 9UVU ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Icatibant — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.